CN114181281A - 用于炎症和纤维化的肽治疗 - Google Patents

用于炎症和纤维化的肽治疗 Download PDF

Info

Publication number
CN114181281A
CN114181281A CN202111595612.6A CN202111595612A CN114181281A CN 114181281 A CN114181281 A CN 114181281A CN 202111595612 A CN202111595612 A CN 202111595612A CN 114181281 A CN114181281 A CN 114181281A
Authority
CN
China
Prior art keywords
peptide
ebp
lys
fibrosis
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111595612.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·赛基亚
M·巴克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN114181281A publication Critical patent/CN114181281A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202111595612.6A 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗 Pending CN114181281A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562160173P 2015-05-12 2015-05-12
US62/160,173 2015-05-12
CN201680024300.0A CN107531752B (zh) 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗
PCT/US2016/026966 WO2016182660A1 (en) 2015-05-12 2016-04-11 Peptide treatment for inflammation and fibrosis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680024300.0A Division CN107531752B (zh) 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗

Publications (1)

Publication Number Publication Date
CN114181281A true CN114181281A (zh) 2022-03-15

Family

ID=57248348

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202111595612.6A Pending CN114181281A (zh) 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗
CN201680024300.0A Active CN107531752B (zh) 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗
CN202210439797.XA Pending CN114621318A (zh) 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201680024300.0A Active CN107531752B (zh) 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗
CN202210439797.XA Pending CN114621318A (zh) 2015-05-12 2016-04-11 用于炎症和纤维化的肽治疗

Country Status (7)

Country Link
US (1) US10434134B2 (https=)
EP (1) EP3294752B1 (https=)
JP (1) JP7372026B2 (https=)
CN (3) CN114181281A (https=)
AU (1) AU2016260190A1 (https=)
CA (1) CA2984769C (https=)
WO (1) WO2016182660A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114621318A (zh) * 2015-05-12 2022-06-14 加利福尼亚大学董事会 用于炎症和纤维化的肽治疗

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
RU2019123160A (ru) * 2016-12-29 2021-01-29 Юниверсити Оф Майами Способ модуляции активности инфламмасом и воспаления в легком
SG11202013176VA (en) 2018-07-03 2021-01-28 Univ Miami Compositions and methods for treating inflammasome related diseases or conditions
JP7659499B2 (ja) * 2018-10-25 2025-04-09 ネクセル カンパニー，リミテッド 線維症を治療又は予防するための組成物及び方法
CN111770539B (zh) 2019-04-02 2021-07-09 大唐移动通信设备有限公司 一种lmf选择方法、终端定位服务方法及装置
WO2021101966A1 (en) * 2019-11-18 2021-05-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of fibrosis with combined blockade of il-6 and immune checkpoint
CN114134191B (zh) * 2020-09-04 2023-12-12 琛蓝(美国)营养制品股份有限公司 一种抗炎护肾的蛤蜊肽的制备方法和应用
CN112960780B (zh) * 2021-03-03 2023-02-03 龙江环保集团股份有限公司 一种生物膜载体的预处理方法及生物法污水处理工艺
DE102022203153A1 (de) 2022-03-31 2023-10-05 Psa Automobiles Sa Stauraumanordnung für einen Innenraum eines Fahrzeugs, Fahrzeug mit der Stauraumanordnung und Verfahren zur Benutzung einer Stauraumanordnung
KR102772405B1 (ko) * 2022-06-10 2025-02-26 (주)케어젠 근육 손실 저해 및 근육량 증진 활성을 갖는 펩타이드 및 이의 용도
CN115850440B (zh) * 2022-12-09 2023-07-11 中国人民解放军陆军军医大学 一种长链MyD88诱饵肽及其作为药物的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141976A1 (en) * 2000-10-27 2004-07-22 Mario Chojkier Treatment of disease by inducing cell apoptosis
US20070041992A1 (en) * 2005-08-19 2007-02-22 Ute Frevert Compositions and methods for inactivating or suppressing inflammatory cells
CN104220098A (zh) * 2012-02-14 2014-12-17 加利福尼亚大学董事会 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129349B2 (en) * 2000-10-27 2012-03-06 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
WO2002054938A2 (en) * 2000-10-27 2002-07-18 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
CN1678336A (zh) * 2002-02-21 2005-10-05 加州大学校务委员会 用细胞凋亡诱导方法治疗疾病
US7119071B2 (en) * 2002-05-21 2006-10-10 University Of Medicine And Dentistry Of New Jersey Amino terminal substance P compositions and methods for using the same
MX2007013430A (es) * 2005-04-29 2008-03-19 Univ California Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
CN101227918A (zh) * 2005-04-29 2008-07-23 加州大学评议会 治疗以炎症反应为特征的病理的肽和肽模拟物
EP2324048A2 (en) * 2008-07-30 2011-05-25 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
HK1198333A1 (zh) * 2011-07-19 2015-04-02 Thrasos Innovation, Inc. 抗纤维化肽及其在用於治疗以纤维化为特徵的疾病和病症的方法中的用途
AU2016260190A1 (en) * 2015-05-12 2017-11-23 The Regents Of The University Of California Peptide treatment for inflammation and fibrosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141976A1 (en) * 2000-10-27 2004-07-22 Mario Chojkier Treatment of disease by inducing cell apoptosis
US20070041992A1 (en) * 2005-08-19 2007-02-22 Ute Frevert Compositions and methods for inactivating or suppressing inflammatory cells
CN104220098A (zh) * 2012-02-14 2014-12-17 加利福尼亚大学董事会 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EMEL CANBAY ET AL: "Intraperitoneal chemotherapy and its evolving role in management of gastric cancer with peritoneal metastases", CHIN J CANCER RES, vol. 26, no. 1, pages 1 - 3 *
高玲: "庆大霉素投药方案合理性的讨论", 中国医院药学杂志, vol. 1, pages 1 - 3 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114621318A (zh) * 2015-05-12 2022-06-14 加利福尼亚大学董事会 用于炎症和纤维化的肽治疗

Also Published As

Publication number Publication date
CN114621318A (zh) 2022-06-14
CA2984769C (en) 2023-03-21
JP2018520999A (ja) 2018-08-02
CN107531752A (zh) 2018-01-02
US20180125919A1 (en) 2018-05-10
CA2984769A1 (en) 2016-11-17
EP3294752B1 (en) 2020-11-04
NZ736840A (en) 2024-05-31
JP7372026B2 (ja) 2023-10-31
AU2016260190A1 (en) 2017-11-23
EP3294752A1 (en) 2018-03-21
US10434134B2 (en) 2019-10-08
CN107531752B (zh) 2022-05-10
WO2016182660A1 (en) 2016-11-17
EP3294752A4 (en) 2018-12-19

Similar Documents

Publication Publication Date Title
CN107531752B (zh) 用于炎症和纤维化的肽治疗
JP6676589B2 (ja) 薬物動態特性の改善されたコンプスタチンアナログ
CN104147591B (zh) Jnk信号转导通路的细胞可渗透性肽抑制剂用于治疗各种疾病的应用
US20190023738A1 (en) Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
ES2871544T3 (es) Péptidos y métodos de uso de los mismos
US20160101158A1 (en) Peptide therapeutics and methods for using same
ES3063182T3 (en) The peptidomimetic compound (r)-2-amino-n-((s)-l-(((s)-5-amino-l-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide for use in the treatment of amyotrophic lateral sclerosis
ES2256070T3 (es) Actividad antimicrobiana de la primera agrupacion cationica de lactoferrina humana.
US20240108740A1 (en) Therapeutic compositions including spn10 and uses thereof
KR102419584B1 (ko) 혈액뇌장벽 투과 펩타이드를 유효성분으로 포함하는 조성물 및 이의 용도
WO2017073764A1 (ja) 新規ｎｋ３受容体アゴニスト
HK40076050A (en) Peptide treatment for inflammation and fibrosis
WO2016144352A2 (en) Therapeutic compositions including acrylamido compounds or phenyl-substituted maleimide compounds, variants thereof and methods of using the same
CN107406513B (zh) 双链分子(bipartite)及其于治疗异常蛋白聚集的用途
US20160279255A1 (en) THERAPEUTIC COMPOSITIONS INCLUDING MODULATORS OF deltaPKC AND/OR epsilonPKC, AND USES THEREOF
US10245298B2 (en) Compositions and methods for treating fibrosis
KR102510514B1 (ko) 세포 살상제
WO2016190852A1 (en) Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof
KR102846910B1 (ko) 항암 활성을 갖는 신규한 펩타이드 및 이의 용도
RU2825641C2 (ru) Способ повышения терапевтической эффективности фексапотида трифлутата при лечении снмп
RU2820132C2 (ru) Способ улучшения симптомов со стороны нижних мочевыводящих путей
RU2839726C2 (ru) Способ лечения симптомов со стороны нижних мочевыводящих путей с использованием фексапотида трифлутата
US20240002441A1 (en) Peptides and uses thereof in modulation of amyloid-beta protein degrading proteases
JP2025160231A (ja) 下部尿路症状を改善する方法
WO2020000061A1 (en) Renal treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination